Form 8-K - Current report:
SEC Accession No. 0001213900-25-041049
Filing Date
2025-05-08
Accepted
2025-05-08 16:05:33
Documents
16
Period of Report
2025-05-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0241397-8k_cadrenal.htm   iXBRL 8-K 24906
2 PRESS RELEASE, ISSUED BY CADRENAL THERAPEUTICS, INC. ON MAY 8, 2025 ea024139701ex99-1_cadrenal.htm EX-99.1 49060
3 GRAPHIC ex99-1_001.jpg GRAPHIC 5897
4 GRAPHIC ex99-1_002.jpg GRAPHIC 5832
  Complete submission text file 0001213900-25-041049.txt   274532

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE cvkd-20250508.xsd EX-101.SCH 3014
6 XBRL LABEL FILE cvkd-20250508_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE cvkd-20250508_pre.xml EX-101.PRE 22358
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0241397-8k_cadrenal_htm.xml XML 3799
Mailing Address 822 A1A NORTH SUITE 306 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 306 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

EIN.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41596 | Film No.: 25925937
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)